Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant pertussis protection following whole-cell versus acellular primary vaccination
ISRCTN17271364Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pertussis filamentous haemagglutinin, Unifive and trivalent inactivated polio vaccine in pertussis (2 arms), sponsored by University of Oxford. Primary endpoint: Pertussis toxin-specific antibody geometric mean concentration at 13 months. Started Mar 2021; status: completed.
02
Drugs
pertussis filamentous haemagglutininUnifivetrivalent inactivated polio vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on ISRCTN17271364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17271364.